We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic's GYN Surgical Segment Looks Poised for Long-Term Growth
Read MoreHide Full Article
Key Takeaways
Hologic's GYN Surgical division delivered $679.8M in fiscal 2025 revenues, marking 6% growth from fiscal 2024.
NovaSure is seeing accelerated adoption internationally, supported by Hologic's go-direct efforts.
HOLX expanded its fibroid treatment portfolio through Acessa, Bolder Surgical and Gynesonics acquisitions.
The global Gynecological Devices market is expanding, supported by the higher prevalence of diseases like PCOS, uterine fibroids and cervical cancer, continued innovation in minimally invasive procedures, as well as greater awareness of women's health and reproductive care. According to Precedence Research, the market is projected to expand at a CAGR of 8.25% through 2025-2034, with the North America region expected to account for the highest revenue share. Massachusetts-based Hologic (HOLX - Free Report) is a strong contender in this space.
The company’s GYN Surgical division posted revenues of $679.8 million in fiscal 2025, a 6% increase over fiscal 2024. Over the years, a combination of internal innovation and product additions through M&A has transformed the segment into a meaningful growth driver. Hologic’s investments in commercial and market access capabilities outside the United States have significantly expanded the reach of its minimally invasive surgical products.
The Myosure devices continue to deliver strong sales internationally than in the United States, highlighting the significant untapped demand for minimally invasive treatments of uterine polyps and fibroids. NovaSure is also seeing rapid adoption overseas, particularly in Europe, driven by the company’s go-direct strategy and improved reimbursement dynamics. Revenue growth is further supported by contributions from the Fluent fluid management system, designed to simplify hysteroscopic procedures.
Inorganically, Hologic acquired Acessa Health in 2020, bringing the Acessa ProVu system, which uses laparoscopic ultrasound, guidance mapping and radiofrequency ablation to treat nearly all types of fibroids. A year later, the company acquired Bolder Surgical, adding laparoscopic vessel sealing, dividing, and dissecting devices to the portfolio and also enabling Hologic to expand the use of Bolder's devices to OB/GYN specialists. Hologic acquired its competitor Gynesonics in fiscal 2025, which enhanced the fibroid treatment portfolio with the Sonata system. Together, all these factors position Hologic’s GYN Surgical segment for sustained long-term growth.
Updates From Hologic’s Peers
Becton, Dickinson and Company (BDX - Free Report) , or BD, has announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania to advance research in deep human immune profiling and support the development of immune-mediated therapies. The collaboration includes developing and validating a high-parameter flow cytometry panel that can capture key functional pathways in whole blood, including phosphorylation markers.
Abbott (ABT - Free Report) has announced the FDA approval for the Volt Pulsed Field Ablation (PFA) system to treat patients battling atrial fibrillation (AFib). Abbott will soon begin commercial PFA cases in the United States and will continue its expansion of sites in the European Union following Volt CE Mark approval earlier this year.
HOLX Stock Performance, Valuation and Estimates
In the past six months, Hologic shares have risen 14.6% compared with the industry’s 14.8% growth.
Image Source: Zacks Investment Research
Hologic is trading at a forward one-year price-to-sales (P/S) of 3.83X, lower than the industry average of 4.41X.
Image Source: Zacks Investment Research
See how analysts are projecting Hologic’s fiscal 2026 and 2027 earnings.
Image: Bigstock
Hologic's GYN Surgical Segment Looks Poised for Long-Term Growth
Key Takeaways
The global Gynecological Devices market is expanding, supported by the higher prevalence of diseases like PCOS, uterine fibroids and cervical cancer, continued innovation in minimally invasive procedures, as well as greater awareness of women's health and reproductive care. According to Precedence Research, the market is projected to expand at a CAGR of 8.25% through 2025-2034, with the North America region expected to account for the highest revenue share. Massachusetts-based Hologic (HOLX - Free Report) is a strong contender in this space.
The company’s GYN Surgical division posted revenues of $679.8 million in fiscal 2025, a 6% increase over fiscal 2024. Over the years, a combination of internal innovation and product additions through M&A has transformed the segment into a meaningful growth driver. Hologic’s investments in commercial and market access capabilities outside the United States have significantly expanded the reach of its minimally invasive surgical products.
The Myosure devices continue to deliver strong sales internationally than in the United States, highlighting the significant untapped demand for minimally invasive treatments of uterine polyps and fibroids. NovaSure is also seeing rapid adoption overseas, particularly in Europe, driven by the company’s go-direct strategy and improved reimbursement dynamics. Revenue growth is further supported by contributions from the Fluent fluid management system, designed to simplify hysteroscopic procedures.
Inorganically, Hologic acquired Acessa Health in 2020, bringing the Acessa ProVu system, which uses laparoscopic ultrasound, guidance mapping and radiofrequency ablation to treat nearly all types of fibroids. A year later, the company acquired Bolder Surgical, adding laparoscopic vessel sealing, dividing, and dissecting devices to the portfolio and also enabling Hologic to expand the use of Bolder's devices to OB/GYN specialists. Hologic acquired its competitor Gynesonics in fiscal 2025, which enhanced the fibroid treatment portfolio with the Sonata system. Together, all these factors position Hologic’s GYN Surgical segment for sustained long-term growth.
Updates From Hologic’s Peers
Becton, Dickinson and Company (BDX - Free Report) , or BD, has announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania to advance research in deep human immune profiling and support the development of immune-mediated therapies. The collaboration includes developing and validating a high-parameter flow cytometry panel that can capture key functional pathways in whole blood, including phosphorylation markers.
Abbott (ABT - Free Report) has announced the FDA approval for the Volt Pulsed Field Ablation (PFA) system to treat patients battling atrial fibrillation (AFib). Abbott will soon begin commercial PFA cases in the United States and will continue its expansion of sites in the European Union following Volt CE Mark approval earlier this year.
HOLX Stock Performance, Valuation and Estimates
In the past six months, Hologic shares have risen 14.6% compared with the industry’s 14.8% growth.
Image Source: Zacks Investment Research
Hologic is trading at a forward one-year price-to-sales (P/S) of 3.83X, lower than the industry average of 4.41X.
Image Source: Zacks Investment Research
See how analysts are projecting Hologic’s fiscal 2026 and 2027 earnings.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.